Alkermes, Inc. investor investigation over possible securities laws violations

If you are an investor in shares of Alkermes, Inc. (NASDAQ:ALKS), and/or have any information relating to the investigation, you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Alkermes
Affected Securities: 
NASDAQ: ALKS

After Alkermes, Inc. lost more than 30% in stock value an investigation on behalf of investors in Alkermes, Inc. (NASDAQ:ALKS) shares concerning potential violations of Federal Securities laws in connection with the New Drug Application for Alkermes’s diabetes drug BYDUREON was announced.

The investigation by a law firm on behalf of investors in ALKS shares concerns whether Alkermes, Inc., certain of its officers, directors or insiders potentially violated any Securities laws in connection with the recent developments surrounding the diabetes drug BYDUREON (TM) (exenatide extended-release for injectable suspension.

Cambridge, Massachusetts based Alkermes, Inc. is an integrated biotechnology company. Alkermes, Inc., Eli Lilly and Company, and Amylin Pharmaceuticals are currently working together to develop BYDUREON, which is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide, the active ingredient in BYETTA(R) (exenatide) injection, in a single weekly dose. BYETTA has been available in the U.S. since June 2005 and is used in more than 60 countries worldwide by adults with type 2 diabetes.

Alkermes, Inc., Eli Lilly and Company, and Amylin Pharmaceuticals submitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BYDUREON in May 2009 based on data that included the DURATION-1 head-to-head clinical study, safety data from DURATION-2 and more than seven years of clinical experience with BYETTA.

Shares of Alkermes, Inc. increased from May 2009 from under $8 per share to as high as almost $16 per share in October 2010.

FDA issued a complete response letter to the companies in March 2010 and in May 2010. ALKS shares decreased from $13.48 in April 2010 to $10.79 per share in May 2010.

ALKS shares regained value over the next months and traded at almost $16 per share during October before ALKS shares dropped more than 30% on Wednesday October 20, 2010.

The evening before the more than 10% decline Alkermes, Inc , Eli Lilly and Company, and Amylin Pharmaceuticals announced after the market closed that the FDA has issued a complete response letter regarding their NDA for BYDUREON. In the complete response letter the FDA requested a thorough QT study with exposures of exenatide higher than typical therapeutic levels of BYDUREON. Additionally, the FDA has now requested the results of the DURATION-5 study to evaluate the efficacy, and the labeling of the safety and effectiveness, of the commercial formulation of BYDUREON.

It is expected that the companies will submit their reply to the complete response letter by the end of 2011, meaning the FDA is unlikely to make a decision until mid-2012, thus representing a potential delay of more than 18 months.
Alkermes reported a decline of almost 50% in 12month total revenue for the past two filing periods. Its 12 month total revenue went from $326.84million reported on March 31, 2009 to $178.28million reported on March 31, 2010. Its Net Income went from a Net Income of $130.50million reported on March 31, 2009 to a net loss of $39.63million reported on March 31, 2010.

The investigation by a law firm on behalf of investors of Alkermes, Inc. seeks to determine when Alkermes, Inc. , certain of its officers and directors, and certain insiders knew about the potential delay and/or knew about any other material information in regards to the BYDUREON matter in violations to Federal Securities Laws.